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Abstract 
 
With statins, the reported rate of adverse events differs widely between randomized clinical 
trials (RCTs) and observations in clinical practice, the rates being 1-2% in RCTs versus 10-20% 
in the so-called real world. One possible explanation is the claim that RCTs mostly use a run-
in period with a statin. This would exclude intolerant patients from being included into RCTs 
and therefore favor a bias towards lower rates of intolerance. 
We here review data from RCTs with more than 1000 participants with and without a run-in 
period, which were included in the Cholesterol Treatment Trialists collaboration (CTTC). Two 
major conclusions arise: 1) The majority of RCTs did not have a test dose of a statin in the run-
in phase. 2) A test dose in the run-in phase was not associated with a significantly improved 
adherence rate within that trial when compared to trials without a test dose. Taken together, 
the RCTs of statins reviewed here do not suggest a bias towards an artificially higher 
adherence rate because of a run-in period with a test dose of the statin.  
Other possible explanations for the apparent disparity between RCTs and real world 
observations are also included in this review albeit mostly not supported by scientific data. 
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Introduction 
Randomized controlled trials (RCTs), especially when large, double-blind and placebo-
controlled, are the best method for evaluating the efficacy, safety and tolerability of statin 
treatment. 1,2 A further advantage is that both, known and – more importantly - unknown 
confounders are equally distributed between the treatment arms. 
There is overwhelming evidence from numerous RCTs that inhibitors of HMG-CoA reductase 
(statins) substantially reduce the risk of myocardial infarction, stroke and other manifestations 
of atherosclerotic cardiovascular disease. Furthermore, analysis of the Cholesterol Treatment 
Trialists` Collaboration (CTTC) showed that statin therapy substantially reduces the risk of 
vascular mortality by about one fifth per each mmol/L reduction in LDL cholesterol. 3 
In addition to results from RCTs, during the approximately 4 decades since their introduction, 
statins have been demonstrated to be safe and well tolerated. 4,5 Adverse effects of statin in 
RCTs, as recently reviewed 6 are mainly myopathy with reportedly 1-2% under statin, with 
similar incidence in placebo arms. 3 Sometimes, however, their perceived tolerability has 
declined. Some investigators nowadays suggest that 10–20% of patients are unable to tolerate 
statins, either completely or at a higher dose. Consequently, poor adherence in the real world 
setting has become an important problem. 7,8 
Specifically, for the case of statin trials, there is an often raised claim that RCT’s excluded 
patients with statin intolerance in the pre-randomization or run-in periods in order to 
minimize losses from follow-up, a fact that could explain why randomized trials had lower 
rates of side effects in the active treatment phase than will be observed in the real world. 9 
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The Physicians' Health Study exemplifies the use of a pre-randomization run-in period to 
exclude subjects who are more likely to become non-adherent. The underlying rationale was 
that run-in periods can dilute or enhance the clinical applicability of the results of a clinical 
trial, depending on the patient group who will receive the therapy. 10 Thus, adherence data 
from clinical trials using run-in periods should clarify how this aspect of their design affects 
the applicability of the results to clinical practice.  
The hypothesis of the present investigation was that there are more side effects non 
adherence in trials without a run-in period. We analyzed the data from RCTs selected by the 
CTTC involving 175.000 participants. 3 
 
Selection of Sources  
We aimed to include all eligible statin trials from the CTTC protocols. The CTTC protocol was 
first established in 1994 to reliably assess mortality outcome in particular types of patients. 
Randomized trials were eligible for inclusion if the main effect of at least one of the trial 
interventions was to modify lipid levels, the trial was un-confounded with respect to the 
intervention and the trial aimed to recruit at least 1000 participants with treatment duration 
of at least two years.11 The main outcome measure in these trials were major vascular events.  
From the 27 trials included in CTTC and the HPS-2 trial, 15 trials had a run-in period. (Fig 1). 
Among the 15 trials with a run-in period, 12 trials used no statin in the run-in period and 3 
trials used a statin therapy in the run-in phase. We here evaluate the adherence rates in these 
trials, both for statins and for placebo. 
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Next, we tested whether the use of statins in the run-in phase affected the rate of 
noncompliance during the trial both in patients receiving statins and those receiving placebo. 
 
Medication in Run-In Phase 
Adherence Rate in CTTC trials without a run-in period 
From the 27 CTTC trials, 13 trials had no run-in period.  
In the MEGA trial 8214 men and postmenopausal women aged 40-70 years were included and 
randomized to diet or diet plus pravastatin (10 to 20mg daily). The mean follow-up was about 
5.3 years.  The adherence rate was 65.6 % in the diet and 65.8% in the diet plus pravastatin 
group over 5-year follow-up. 12 
In the ALERT trial 2102 renal transplant recipients, men and women aged 30-75 years, were 
included and randomized to fluvastatin XL (80mg/day) or placebo. Patients with a pre-existing 
statin therapy were excluded. The mean follow-up was about 5.1 years. The adherence rate 
was 74.9% in the fluvastatin group and 71.5% in the placebo group. 13 
The CARDS trial with 2838 men and women with type 2 diabetes aged 40 to 75 years in 132 
UK and Ireland centres to placebo or atorvastatin. The mean duration of follow-up was 3.9 
years. The trial was terminated earlier because of the pre-specified rule for efficacy. The 
adherence rate was >99% in both groups. 14 
In the ALLHAT-LLT trial a subset of 10.355 patients were randomized to a lipid lowering 
component with pravastatin 40mg/day or usual care. The follow-up was 4.9 years. There is no 
concrete information on adherence in the lipid subgroup. 15 
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In the Post CABG trial 1351 men and women, aged 21 to 74 years, who had undergone a 
coronary bypass surgery 1 to 11 years before baseline. Patients were randomized to 
aggressive versus moderate lipid lowering therapy with lovastatin (mean 76mg daily) and 
cholestyramine (8g per day) if necessary. An angiography was repeated after an average of 
4.2 years. The adherence in both statin groups was 85 to 90%. The cholestyramine adherence 
was lower (65%). 16 
The CARE trial included 4159 patients, men and postmenopausal women aged 21-74 years 
with myocardial infarction who were randomized to pravastatin (40mg/day) or placebo. In the 
last year of follow-up, 86% of the placebo group and 94% of the treatment group were taking 
their study medication. The median duration of follow-up was 5.0 years. 17 
In the ALLIANCE trial 2442 patients, men and women >18 years, with coronary heart disease 
were randomized to an aggressive treatment arm using atorvastatin (80mg/day) or usual care 
followed over 51.5 months. The adherence was 78.7% in the aggressive treatment arm and 
76.8% in the usual care arm. 18 
In the LIPS trial 1677 patients, men and women aged 18-80 years with stable or unstable 
angina, were randomly assigned to treatment with fluvastatin or placebo. The median follow-
up was 3.9 years. The adherence was 93.1% in the fluvastatin group and 92.1% in the placebo 
group. 19 
The AURORA trial included 2776 men and women aged 50-80 years who were undergoing 
maintenance dialysis. They were randomized to rosuvastatin 10mg daily or placebo. The 
median follow-up period was 3.8 years. According to tablet counts, 91.7% of rosuvastatin and 
89.5% of placebo tablets were taken as prescribed. 20 
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The 4D trial included 1255 subjects, men and women 18-80 years, with type 2 diabetes 
receiving maintenance haemodialysis. They were randomly assigned to atorvastatin 20mg per 
day or placebo. The median follow-up time was about 4 years. In the placebo group, 82% of 
patients took the study medication without interruption and in the atorvastatin group 80% of 
patients did so. 21 
The A-Z trial compared in phase Z in 4497 patients with acute coronary syndrome aged 21-80 
years with a less aggressive treatment strategy with placebo (for 30 days) then simvastatin 
20mg or more aggressive with simvastatin 40mg (for 30 days) and then 80mg. The adherence 
rate was about 68% in the low aggressive group and about 66% in the more aggressive group. 
They were randomized to either an early intensive treatment strategy (40mg/day of 
simvastatin for 30 days and then 80mg/day of simvastatin thereafter) or a less aggressive 
strategy (placebo for 4 months and then 20mg/day of simvastatin thereafter). 22 
The PROVE-IT trial randomized 4162 patients, men and women at least 18 years old, who were 
hospitalized for an acute coronary syndrome to a treatment group with pravastatin 40mg or 
a group with atorvastatin 80mg. The follow-up was up to 36 months. The adherence rate has 
not been reported in detail from this trial. 23 
The IDEAL trial enrolled 8888 patients, men and women, aged <80 years with a history of acute 
myocardial infarction.  They compared usual dose simvastatin (20mg/day) or high dose of 
atorvastatin (80mg/day). The follow-up was about 4.8 years. The adherence was 95% in both 
groups. 24 
In synopsis, thus, in those trials that had no run-in phase, the adherence rate was very similar 
in patients receiving statins and in those receiving placebo. 
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Adherence Rate in CTTC trials with a run-in period 
From the 27 CTTC trials plus HPS-2, 15 trials had a run-in period. (Fig. 1).  
The 4S trial randomised 4444 men and women aged 35 – 70 with a history of angina pectoris 
or myocardial infarction from 94 Scandinavian centres. The protocol included a two-week 
placebo run-in phase. There was no significant difference in discontinuation (288 (13%) 
patients in placebo group vs. 231 (10%) in the statin group). 25 
A similar report exists from the ASCOT-LLA trial with 10.305 hypertensive patients aged 40-79 
and a total cholesterol of 6.5 mmol/l or less. There was a 4-week run-in period. In the 
atorvastatin group (10mg/day), 240 patients (2.3%) discontinued atorvastatin vs. 276 (2.6%) 
in the placebo group. 26 
In the ASPEN trial, 3598 men and women with type 2 diabetes aged 40-75 years had a 6 -week 
run-in phase, 67.5% in the Atorvastatin group (10mg/day) and 57.6% in placebo group were 
taking study medication at study completion. 27 
The AFCAPS/TexCAPS included 6605 men and women aged 45-73 years. There was a 2-week 
placebo run-in phase, 969 patients (14.6%) withdraw in the Lovastatin group vs. 1220 (18.4%) 
in the placebo group. 28 
The HPS study with 20.536 participants (men and women) with coronary disease or other 
occlusive arterial disease aged 40 – 80 years had a 4-week placebo run-in phase and showed 
an adherence rate of 99.6% in the simvastatin (20 mg/d) intervention group vs. 99.7% in the 
placebo group.. 29 
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The CORONA trial included 5459 participants of at least 60 years of age. Eligible patients were 
treated with single blind placebo for 2 to 4 weeks before randomization to demonstrate 
compliance. After 33 months of follow-up median rosuvastatin (10mg/day) was discontinued 
in 546 patients in the rosuvastatin group (10%) vs. 490 in the placebo group (8.9%), the 
difference was not statistically significant. 30 
A similar result was shown in the PROSPER trial with 5804 men and women aged 70-82 years, 
with a history or risk for vascular disease. The eligible patients entered a 4-week single blind 
placebo lead-in period. Participants who used less than 75% or more than 120% of the placebo 
medication were excluded; 725 (12.5%) patients discontinued in the placebo group vs. 724 
(12.5%) in the pravastatin group (40mg/day) during a follow-up of 3.2 years. 31 
In the JUPITER trial, 17802 healthy men 50 years and women 60 years or older were included. 
They had no history of CAD or lipid lowering medication. All eligible subjects underwent a 4-
week run-in phase during which they received placebo. The adherence rate was about 75% at 
the time the study was terminated. There are no data on the comparison of placebo and 
verum. We should mention that the patients received rosuvastatin 20mg daily. The trial was 
stopped after a median follow-up of 1.9 years. 32 
The SEARCH study with 12.064 patients aged between 18 to 80 years with a history of MCI 
had a run-in phase with simvastatin 20mg. In the active phase of the trial, the patients were 
then randomised to 80mg simvastatin or 20mg simvastatin. The adherence after 84 months 
was 77% in the simvastatin 80mg group vs. 69% in the simvastatin 20mg group. 33 
The WOSCOPS trial compared pravastatin 40mg with placebo in 6596 patients in a 4.9 year 
follow up. The patients got a lipid lowering advice after 1 week and a control diet for 4 weeks 
Downloaded from https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvy028/5067834
by Aalborg University Library user
on 14 August 2018
before randomisation. The adherence rate was 69.2% in the placebo group and 71.4% in the 
pravastatin group, respectively. 34 
The GDDS trial included 1255 patients with type 2 diabetes at the age of 18 -80 years with 
hemodialysis for less than 2 years. The patients were randomized to atorvastatin 20mg or 
placebo, after a 4-week run-in phase with placebo. After a 4 year follow up, the adherence 
rate was 80% in the treatment group and 82% in the placebo group. 35 
The HPS 2 trial included 25.673 patients with occlusive arterial disease. There was a 4-week 
run-in phase with simvastatin 40mg. If the participants did not reach the treatment goal they 
received ezetimibe on top. The proportion of participants taking at least 80% of their study 
medication was 92, 89 and 85% after 1,2, and 3 years follow up, respectively. 29 
The GISSI-P trial included 4271 patients with acute myocardial infarction. The population on 
which the cholesterol lowering treatment was tested (pravastatin 20mg daily) was derived 
from a broader cohort randomized to supplements of n-3 polyunsaturated fatty acids, vitamin 
E, or standard treatment over 6 months.  The median follow-up was about 23 months.36 
In synopsis thus, there is no indication that - in studies using a run-in phase - a difference 
existed in adherence between participants allocated to placebo or to statins. Moreover, and 
most importantly, there is no significant difference in adherence rates between trials using or 
not using statins in the run-in phase (Figure 2). A run-in phase statin use cannot be a cause for 
the low rate of statin non-adherence in RCTs. 
The general value of run-in phases in RCTs has recently been challenged in investigations on 
DPP4 inhibitors and statins. 37,38 The authors had focused on efficacy and safety, but not on 
adherence rates. Taken together with our results, statins in the run-in phase are time-
consuming and appear not essential for the conduct of RCTs. 
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Other Causes for Non-adherence in the Real world vs. RCT’s 
  
In general, non-adherence in real-world settings can exceed 50% in some populations, and 
this situation also pertains to non-medication treatment recommendations such as 
monitoring blood glucose or exercising regularly. 39,40 Multiple factors contribute to real-world 
non-adherence, including high medication costs, complexity and duration of the medication 
regimen, disruption of lifestyle, younger age, asymptomatic chronic disease,  the patient’s 
opinion of benefits and risks, and poor communication between doctor and patient. 41,42 
Treatment factors, particularly side effects such as weight gain or sexual dysfunction, patient 
factors, such as the desire to be independent and eschew the healthcare system, and illness 
factors (including psychosis, depression, or cognitive impairment) are also important 
contributors to non-adherence. 43 
Importantly, non-adherence during the conduct of a clinical trial will include most types of 
non-adherence encountered in real world plus several behaviours unique to clinical trials that 
are termed, according to Shiovitz et al. as “artifactual” non-adherence. 44 When adherence is 
not monitored, there is a general assumption that adherence is almost ideal in clinical trial 
settings. 45 However, there is extensive evidence to the contrary: both real-world and the 
unique forms of non-adherence abound in clinical trials.46 Artifactual non-adherence is 
completely different from real-world non-adherence; it is also contrary to both the clinical 
trial protocol and the agreements in the informed consent process. Examples of these specific 
and intentional behaviours include denying previous or ongoing study participation while 
enrolling in multiple studies with an intention to collect stipends, but pretending to have the 
medical interest. 44 
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Although real world studies have been extremely valuable for identifying associations of risk 
factors with disease (eg., blood pressure, blood sugar and cholesterol with cardiovascular 
disease), their value for the assessment of a treatment effects is more limited. Real world 
studies also have the potential to detect large adverse event rates on health outcomes that 
would not normally be expected to occur. One of the best examples certainly is myopathy 
with statin therapy. 47  The HPS study exemplifies very well that patients asked about muscle 
complaints frequently agree to have muscle pain; however this statement was at the same 
frequency found in placebo patients.  
Because of the potential biases inherent in observational studies, they cannot be relied on for 
demonstrating the causal nature of treatment-related associations when the relative risks are 
moderate or relate to health outcomes that are common in the types of patients studied. 48–
53 Thus, when large-scale evidence from randomised controlled trials does exist, the additional 
value of information from non-randomised observational studies about treatment effects is 
very limited  because no causal proof exists. 47  
Contrary to a common belief, adequate data about the use of a treatment in health-care 
databases might not involve a duration of exposure that is longer than in the randomised 
trials. 54–56 Another important fact is that potential biases in observational studies of 
treatment are often underestimated in the interpretation of associations that are found with 
health outcomes. Compared with the situation in randomized controlled trials with masked 
treatment, patients are treated in daily practice knowing that they are taking a particular drug. 
48–50,53,57 Confounding by indication, or contraindication, occurs when the treatment being 
considered tends to be provided more, or less, often to individuals with medical conditions or 
other characteristics that are associated with increased, or decreased, risks of various health 
outcomes (which is, of course, what would be expected to occur in clinical practice) 58. Hence 
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confounders for side effects occur in the real world that are controlled for by randomisation 
in RCTs.  
Moreover, there is a high probability of a nocebo effect. Typically, in a pre-medication 
discussion, physicians tell patients that the treatment could have potential side effects. This 
effect is so called the nocebo effect which refers by definition to the induction or the 
worsening of symptoms induced by sham or active therapies. Examples are numerous and 
concern both clinical trials and daily practice. The underlying mechanisms are, on one hand, 
psychological (conditioning and negative expectations) and, on the other hand, 
neurobiological (role of cholecystokinin, endogenous opioids and dopamine). Nocebo effects 
can modulate the outcome of a given therapy in a negative way, as do placebo effects in a 
positive way. 59 Importantly, in RCTs nocebo effects will be distributed evenly between active 
drug and placebo if the expected side effect is explained equally. As indicated above, 
myopathy rates in the HPS trial (high but equal with placebo and active drug) are a good 
example. 
A recent review of the evidence from randomised trials and observational studies suggested 
that symptomatic adverse events may be misattributed to statins, 50 and there is further 
evidence from trials of statins of this misattribution. 60 Uncertainty about the association 
between muscle symptoms and statins persists due to limitations of observational studies and 
trials. For example, a major limitation of observational studies is a lack of blinding; patients 
taking a medication expect to experience adverse effects,61 and therefore reporting of 
symptoms in statin users may be higher than in a comparable population not on statins.   
Furthermore, many patients start with exercise after a cardiovascular event at the same time 
as statin therapy is initiated, so the causal muscle pain is pushed to statin therapy.  
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Often forgotten is that tolerability is a patient-defined entity and not an objectively defined 
one but a feeling of treated subjects. In addition to all above mentioned reasons there is place 
for irrationality. 
Data on adherence and persistence should ideally be derived from real-life studies. Several 
patient-related, physician-related and health system-related factors influence adherence 
behaviour. 62  Non-adherence may arise from low social status, suboptimal health literacy, lack 
of involvement in treatment decision-making, comorbidity and subsequent polypharmacy, 
communication barriers, uncertainty about the drug effectiveness, serious adverse events 
occurring during therapy, limited access to care, lack of health information technology and 
high copayments 62,63 
 
 
Conclusion 
 If RCT`s have no confounder, real word data must have 
In clinical practice, management of patients with statin intolerance or those with statin 
associated muscle symptoms is often difficult. 64 Strategies for keeping patients on statin 
therapy and improving the adherence have been proposed most recently by two position 
papers of the ESC working group of cardiovascular pharmacotherapy. 7 65 
In most patients, statin associated muscle symptoms are not of pharmacological origin, but 
rather a consequence of the high prevalence of any other background muscle symptoms 
coupled with patient expectations that muscle pain or damage may occur. This problem is 
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aggravated by lay press misinformation. In observational studies of patients prescribed statins 
in clinical practice, adverse event rates, especially muscle symptoms, obtained per 
questionnaire are substantial, but muscle symptoms are also very common in patients 
allocated to placebo. Association is not causation and an adverse event is not necessarily and 
adverse effect. In RCT’s, in which treatment is blinded and the nocebo effect applies equally 
to the statin and placebo groups, there is little difference between statin and placebo in the 
rates of withdrawal due to adverse events of any kind, showing that statins can be tolerated 
by nearly all patients, including those with advanced disease and complex medical history.  
 
Ways to solution   
There appear three levels for a possible progress in statin adherence rate. First, physicians 
should explain causality of benefit and lack of causation of side effects with statins. Second, 
patients must be educated on the long-term value to reduce hard endpoints.  Third, the public 
high-quality media must be informed and convinced of the benefit/risk ratio of statins. 
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Fig. 1: Included trials 
 
 
 
 
 
 
 
HPS denotes Heart Protection Study  
CTTC denotes Cholesterol  Treatment Trialist Collaboration  
 
Table 1 
Studies with a run-in phase  
Study with run-in 
period 
Number 
of 
patients  
Placebo / 
Comparator 
Study drug Duration 
SSSS 4444 Placebo Simvastatin 20mg 5.4 years 
ASCOT 10305 Placebo Atorvastatin 0mg 5 years 
ASPEN  2901 Placebo  Atorvastatin 10mg  4 years 
AFCAPS/TexCAPS 6695 Placebo Lovastatin 20mg (40mg)  5.2 years 
GISSI 4271 Placebo Pravastatin 20mg 23 month 
HPS 20536 Placebo Simvastatin 20mg  5 years 
HPS 2  36059 Placebo ERN/LRPT 3.6 years 
CORONA 5459 Placebo Rosuvastatin 10mg 32.8 month 
TNT 10003 Atorvastatin 10mg  Atorvastatin 80mg 5.5 years 
Lipid Study Group 9014 Placebo Pravastatin 6.1 years 
PROSPER 5804 Placebo Pravastatin 40mg  3.2 years 
JUPITER 17802 Placebo Rosuvastatin 20mg  1.9 years 
SEARCH 12064 Simvastatin 20mg  Simvastatin 80mg  84 months 
WOSCOPS 6596 Placebo Pravastatin 40mg 4.9 years 
German Diabetes 
and Dialysis Study 
1255 Placebo Atorvastatin 20mg  4 years 
 
27 CTTC Trials 
plus HPS- 2 
13 without a run-
in period 
15 with a run-in 
period 
3 with a statin in 
run-in phase 
12 without a 
statin in run-in 
phase 
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Figure 2 
Adherence Rates in Relation to Run-In Phase
 
Mean +- SD  adherence rates in statin trials with vs. without statin therapy in run-in period 
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